Treace Medical Concepts, Inc. TMCI
We take great care to ensure that the data presented and summarized in this overview for TREACE MEDICAL CONCEPTS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMCI
View all-
Armistice Capital, LLC New York, NY6.2MShares$52.5 Million0.6% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$34.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.27MShares$27.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$23.2 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL2.39MShares$20.3 Million0.04% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M2.06MShares$17.4 Million0.0% of portfolio
-
Cibc Private Wealth Group, LLC1.89MShares$16 Million0.02% of portfolio
-
Gagnon Securities LLC1.77MShares$15 Million2.17% of portfolio
-
Jpmorgan Chase & CO New York, NY1.26MShares$10.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.14MShares$9.69 Million0.01% of portfolio
Latest Institutional Activity in TMCI
Top Purchases
Top Sells
About TMCI
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Insider Transactions at TMCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 10
2025
|
John T. Treace Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,905
-0.18%
|
-
|
|
Jan 10
2025
|
Aaron Berutti SVP, Sales |
SELL
Payment of exercise price or tax liability
|
Direct |
4,821
-2.91%
|
-
|
|
Jan 10
2025
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
SELL
Payment of exercise price or tax liability
|
Direct |
4,544
-1.01%
|
-
|
|
Jan 10
2025
|
Sean F. Scanlan Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,821
-2.1%
|
-
|
|
Jan 10
2025
|
Mark Hair Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,594
-2.34%
|
-
|
|
Dec 01
2024
|
Guy Guglielmino Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
363,000
+29.17%
|
-
|
|
Nov 11
2024
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
SELL
Payment of exercise price or tax liability
|
Direct |
3,787
-0.84%
|
$30,296
$8.29 P/Share
|
|
Nov 11
2024
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
BUY
Grant, award, or other acquisition
|
Direct |
15,550
+3.31%
|
-
|
|
Sep 30
2024
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+31.35%
|
-
|
|
Sep 16
2024
|
John T. Treace Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+0.76%
|
$250,000
$5.31 P/Share
|
|
Sep 12
2024
|
Sean F. Scanlan Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,750
+11.89%
|
$0
$0.1 P/Share
|
|
Aug 15
2024
|
James T Treace |
BUY
Open market or private purchase
|
Direct |
84,000
+6.42%
|
$420,000
$5.96 P/Share
|
|
Aug 14
2024
|
John T. Treace Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
85,000
+1.3%
|
$510,000
$6.0 P/Share
|
|
Aug 09
2024
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
BUY
Grant, award, or other acquisition
|
Direct |
129,540
+35.25%
|
-
|
|
Aug 09
2024
|
Mark Hair Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
207,260
+36.03%
|
-
|
|
Aug 09
2024
|
Sean F. Scanlan Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,900
+35.85%
|
-
|
|
Aug 09
2024
|
Aaron Berutti SVP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
60,450
+26.72%
|
-
|
|
Jun 11
2024
|
John T. Treace Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+0.7%
|
$225,000
$5.88 P/Share
|
|
May 31
2024
|
James T Treace |
BUY
Open market or private purchase
|
Direct |
25,000
+2.15%
|
$150,000
$6.05 P/Share
|
|
May 29
2024
|
James T Treace |
BUY
Open market or private purchase
|
Direct |
25,000
+2.19%
|
$125,000
$5.2 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.2M shares |
|---|---|
| Open market or private purchase | 1.47M shares |
| Exercise of conversion of derivative security | 33.8K shares |
| Payment of exercise price or tax liability | 56.9K shares |
|---|